HEMATOLOGY

Treating An Elderly Woman with Chronic Lymphocytic Leukemia

The combination of ibrutinib and obinutuzumab has gained FDA approval for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, based on data from the phase III iLLUMINATE trial.

General Cancer

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.

Umbralisib was granted a breakthrough therapy designation by the FDA for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20 regimen.

Brian T. Hill, MD, PhD, discusses data from a retrospective trial looking at the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with diffuse large B-cell lymphoma.

Mohamad Mohty, MD, PhD, discusses the promise of CAR T-cell therapy in hematologic malignancies. He says CAR T cells were the superstar of the 2018 ASH Annual Meeting.